IOPIDINE
LOE Approachingapraclonidine hydrochloride ophthalmic solution
NDAOPHTHALMICSOLUTION/DROPS
Approved
Dec 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
IOPIDINE (apraclonidine hydrochloride ophthalmic solution) is apraclonidine is a relatively selective, alpha adrenergic agonist and does not have significant membrane stabilizing (local anesthetic) activity. First approved in 1987.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IOPIDINE is an ophthalmic solution containing apraclonidine hydrochloride, a selective alpha-2 adrenergic agonist that reduces intraocular pressure (IOP) by decreasing aqueous humor formation. It is indicated for prevention and management of acute IOP elevation following argon laser trabeculoplasty, argon laser iridotomy, and Nd:YAG laser procedures. The drug acts within one hour with maximum effect at 3–5 hours post-instillation.
$0.105MPart D
LOE ApproachingDeclining
Minimal commercial momentum; brand team likely focused on maintenance and managed decline rather than growth initiatives.
Mechanism of Action
Apraclonidine is a relatively selective, alpha adrenergic agonist and does not have significant membrane stabilizing (local anesthetic) activity. When instilled into the eye, IOPIDINE 1% (apraclonidine hydrochloride ophthalmic solution) has the action of reducing intraocular pressure (IOP).…
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.